The SCIg market is growing rapidly, with KORU Medical Systems outperforming competitors by capturing market share. Read why I ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

Past efforts to allow more religion in public schools have been hamstrung by legal challenges. But those on the religious ...

High Definition Vehicle Insurance (HDVI), a technology-driven commercial auto insurance provider, has secured $40 million in growth capital, bringing its total funding to over $87 million. The round, ...

Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

For the secondary endpoint of mean change in daily “good on” time ... The most common adverse events, per the release, were infusion-site nodule, nausea, somnolence, dyskinesia, headache ...

Leqembi and Kisunla are given as an intravenous (IV) infusion, meaning patients and caretakers often must travel to specialty health centers once or twice a month for an infusion. That could soon ...